Cargando…

Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment

BACKGROUND: Ustekinumab, a human-derived monoclonal antibody that targets the p40 subunit of interleukin (IL)-12 and IL-23, has excellent clinical efficacy and safety in treating psoriasis, with a long half-life. However, no reports have described the use of human skin/serum samples to elucidate its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jiong, Shen, Ji-Yang, Liu, Lun-Fei, Chen, Ji-Su, Dou, Ting-Ting, Zheng, Min, Cai, Sui-Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977627/ https://www.ncbi.nlm.nih.gov/pubmed/31910201 http://dx.doi.org/10.12659/MSM.920371

Ejemplares similares

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010)

Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris
por: Lee, Edmund, et al.
Publicado: (2004)

Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
por: Burlando, Martina, et al.
Publicado: (2020)

The p40 Subunit of Interleukin (IL)-12 Promotes Stabilization and Export of the p35 Subunit: IMPLICATIONS FOR IMPROVED IL-12 CYTOKINE PRODUCTION
por: Jalah, Rashmi, et al.
Publicado: (2013)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways
por: Espígol-Frigolé, Georgina, et al.
Publicado: (2018)

IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt
por: Fiechter, Renée H., et al.
Publicado: (2021)

Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer
por: Quatresooz, Pascale, et al.
Publicado: (2012)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)

Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment
por: Johansson, Per, et al.
Publicado: (2017)

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom
por: Warren, R.B., et al.
Publicado: (2018)

Paradoxical Flare of Psoriasis after Ustekinumab Therapy
por: Lee, Ho Yeol, et al.
Publicado: (2017)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
por: Lynch, Maeve, et al.
Publicado: (2017)

Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab
por: Hsiao, Chuan-Yu, et al.
Publicado: (2017)

Statment on proposals P23, P25 and P35
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1975)

Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009)

Recalcitrant psoriasis responding to new bilogic drug: Ustekinumab
por: Husein-ElAhmed, Husein, et al.
Publicado: (2013)

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019)

Genome-Wide Association Study of Ustekinumab Response in Psoriasis
por: Connell, William T., et al.
Publicado: (2022)

Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations
por: Yang, Seungkeol, et al.
Publicado: (2021)

Suppression of IL‐12/IL‐23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon‐γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon‐driven diseases
por: Vincken, Nanette L. A., et al.
Publicado: (2022)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton, Philip, et al.
Publicado: (2021)

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis
por: Krulig, Eliana, et al.
Publicado: (2010)

Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
por: Hermanns-Lê, Trinh, et al.
Publicado: (2012)

Influence of ustekinumab on body weight of patients with psoriasis: an initial report
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2014)

Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases
por: Kim, Ye Seul, et al.
Publicado: (2016)

Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis
por: Tonini, Annalisa, et al.
Publicado: (2019)

Listeria Meningitis in a Patient With Plaque Psoriasis on Ustekinumab Therapy
por: Roy, Moni, et al.
Publicado: (2022)

Measurement of IL‐12 (p40, p35), IL‐23p19, and IFN‐γ mRNA in Duodenal Biopsies of Cats with Inflammatory Enteropathy
por: Waly, N.E., et al.
Publicado: (2013)

Sorption of Interleukins 12 and 23 Using the Developed Magnetocontrollable Ustekinumab-Based Sorbent
por: Gontar, I.P., et al.
Publicado: (2020)

IL12 p35 and p40 subunit genes administered as pPAL plasmid constructs do not improve protection of pPAL-LACK vaccine against canine leishmaniasis
por: Alcolea, Pedro J., et al.
Publicado: (2019)

Comparison of the risk of heart failure in psoriasis patients using anti‐TNF α inhibitors and ustekinumab
por: Han, Ju Hee, et al.
Publicado: (2022)

Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
por: Avgerinou, Georgia, et al.
Publicado: (2012)

The use of ustekinumab in a patient with severe psoriasis and positive HBV serology()
por: Steglich, Raquel Bissacotti, et al.
Publicado: (2014)

Recapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab
por: Jayasekera, Prativa S., et al.
Publicado: (2016)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
por: Brummer, Grace C., et al.
Publicado: (2017)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ms890ktc0pbt187cr95gsac0hd